Advances in the treatment of Systemic Lupus Erythematosus: from back to the future, to the future and beyond

Publication date: Available online 19 September 2018Source: Joint Bone SpineAuthor(s): Renaud Felten, Florence Scher, Jean Sibilia, François Chasset, Laurent ArnaudABSTRACTThere have been many advances in the diagnosis and therapeutic management of Systemic Lupus Erythematosus (SLE) over the past decades. Following more than eleven centuries of therapeutic uncertainty, the discovery of the therapeutic properties of glucocorticoids is without any doubt one of the most significant advance in the field of autoimmune diseases. The many progresses made by rapidly growing chemical industry of the 19th century chemistry have allowed the identification of valuable therapeutic compounds such as antimalarials, cyclophosphamide, azathioprine, cyclosporine and later mycophenolate mofetil, which have all profoundly changed the face of the disease. A very visible consequence of this is the profound improvement in the prognosis of the disease, with 10-year survival rates of more than 90% in most dedicated centers. Following the development of biotherapies in rheumatoid arthritis, the late 20th century has slowly opened a new era for the treatment of SLE, that of targeted therapies. With the approval of belimumab in 2011 and 74 targeted therapies in clinical development, we may expect great changes in the therapeutic management of SLE. Those molecules target inflammatory cytokines or chemokines and their receptors, B cells or plasma cells, intracellular signalling pathways, B/T cells co-sti...
Source: Joint Bone Spine - Category: Orthopaedics Source Type: research